Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Relapses, also known as exacerbations, flares, or attacks, are common in multiple sclerosis. In fact, in the most common type of multiple sclerosis (MS), relapsing-remitting MS (RRMS), relapses, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback